Valion Bio, Inc. (VBIO) is a Nasdaq-listed, late-stage biopharmaceutical and immunotherapeutics company—formerly Tivic Health Systems, renamed in April 2026—whose lead candidate, Entolimod, is a TLR5 agonist being developed to treat Acute Radiation Syndrome (ARS). With shares recently changing hands near $1.19, the question of whether the stock can reclaim $2.50 is less about a published analyst target and more about whether a heavily diluted micro-cap can hold a technical recovery.
VBIO does not have enough credible analyst price targets to form a meaningful aggregate, so the $2.50 objective follows the fallback method rather than an analyst consensus. The only rating currently tracked is a "Sell" from Weiss Ratings with no accompanying price target. A widely circulated "$210" figure appears in one financial data feed but represents a ~20,288% implied upside—a clear data error, not a genuine, attributable forecast—and is excluded.
The $2.50 level instead rests on identifiable technical discussion: it sits just below the stock's 50-day moving average (around $2.85) and just above the roughly $2.48 level at which shares traded in early October 2026, defining a near-term recovery zone. It is clearly stated here that $2.50 comes from public technical and valuation discussion, not from any analyst or firm's published target.
At roughly $1.19 per share, VBIO carries a market capitalization of only about $2.3 million, placing it firmly in nano-cap territory. Reaching $2.50 would require an increase of approximately 110%, a very large move. The path would effectively be a recovery back to levels the stock touched only weeks earlier in early October, before another leg lower.
The shares have collapsed roughly 98% over the trailing 52 weeks, from a 52-week high near $74.00 to a low near $1.045, reflecting a 1-for-25 reverse split in August 2026 and persistent financing-driven selling pressure. Any move toward $2.50 would depend less on near-term fundamentals and more on a stabilization of the capital structure and renewed speculative interest in the radiation-countermeasure story.
Several developments give the bull case a factual basis. Entolimod is being developed under the FDA's "Animal Rule," with Fast Track and Orphan Drug designations, for Acute Radiation Syndrome—a niche with national-security and government-procurement relevance. Ukraine's Ministry of Health has accepted the company's regulatory dossier for Entolimod, and the company has pointed to U.S. government-funded studies with BARDA, NIAID, and AFRRI, though it has cautioned that such funding "may not be formalized."
In addition, Valion and Shear Kershman Laboratories announced completion of formulation work on an oral mucosal version of Entolimod, potentially creating a second, more scalable delivery pathway. The company also operates a CDMO (contract development and manufacturing organization) subsidiary that could generate service revenue over time. Positive pharmacokinetic data or a binding government contract would be the clearest catalysts.
The obstacles are substantial. VBIO is pre-revenue, posting a $6.2 million first-quarter 2026 loss and negative operating margins, with trailing twelve-month revenue effectively negligible. Financing is dilutive: a $7.74 million raise in August 2026 saw $6.14 million repay obligations to investor 3i, leaving only about $1.5 million in cash for the company.
In October 2026 the company filed a $100 million shelf registration with a $5 million at-the-market (ATM) tranche, and shares outstanding have risen roughly 297% year over year. The August reverse split was itself a response to a Nasdaq minimum-bid deficiency notice, and renewed dilution or a further slide toward $1.00 would make $2.50 harder to reach. Short interest near 10% of the float adds volatility in both directions.
Technically, the picture is weak but offers reference points. The 50-day moving average sits near $2.85 and the 200-day moving average near $16.42, reflecting how far the stock has fallen. The 52-week range is approximately $1.045 to $74.00, and the relative strength index (RSI) has been near oversold territory (around 27). The $2.50 target sits just below the 50-day moving average, meaning that level would also act as a resistance zone on any recovery; a sustained break above roughly $2.85 would be the next technical milestone, with the roughly $7.75 60-day high further overhead.
Analyst price targets typically reflect a roughly 12-month research horizon, but no such horizon exists here because there is no usable analyst coverage. Investors should instead monitor company-specific and technical signals: the next quarterly earnings report (estimated around November 13, 2026), results of the oral Entolimod pharmacokinetic study, any formalization of BARDA or other government funding, progress on the Ukrainian regulatory dossier, the effectiveness and use of the $100 million shelf and $5 million ATM, and maintenance of the Nasdaq $1.00 minimum-bid requirement.
Traders seeking a more systematic way to track volatile micro-cap names can turn to Tickeron's AI Daily Buy/Sell Signals. This tool uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. It is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently—particularly useful for a low-priced, high-volatility name like VBIO, where timing and discipline matter more than a static forecast.
Can VBIO reach $2.50? The question is best framed around a technical recovery rather than an analyst-backed forecast, since no credible price-target consensus exists. A move from $1.19 to $2.50 would require roughly 110% upside—very large by any standard—and would depend on the company stabilizing its capital structure, avoiding further heavy dilution, and converting its Entolimod milestones into binding contracts or positive data. The radiation-countermeasure thesis is real, but it remains upstream of revenue and heavily dependent on financing. Investors should weigh that scientific optionality against a history of reverse splits, dilution, and a near-$1.00 bid price, and monitor the upcoming catalysts rather than assume any particular outcome.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that VBIO and SNGX have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that VBIO and SNGX's prices will move in lockstep.
| Ticker / NAME | Correlation To VBIO | 1D Price Change % | ||
|---|---|---|---|---|
| VBIO | 100% | -5.88% | ||
| SNGX - VBIO | 25% Poorly correlated | +2.48% | ||
| DARE - VBIO | 25% Poorly correlated | -0.15% | ||
| ENLV - VBIO | 23% Poorly correlated | -9.61% | ||
| BNTC - VBIO | 23% Poorly correlated | -5.97% | ||
| RNAC - VBIO | 23% Poorly correlated | +0.39% | ||
More | ||||